Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-CRC-064 dose optimization study of ABBV-400 in refractory metastatic colorectal cancer
jRCT2031240653Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Objective response, Adverse events and 3 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2031240653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240653.